[CAS NO. 853426-35-4] Blinatumomab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [853426-35-4]

Catalog

HY-P9963

Brand

MCE

CAS

853426-35-4

DESCRIPTION [853426-35-4]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Blinatumomab]

For research use only. We do not sell to patients.

Summary

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00560794	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	January 2008	Phase 2
NCT04723342	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Childhood Acute Lymphoblastic Leukemia	February 1, 2020	Not Applicable
NCT02790515	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myeloid Sarcoma\|Chronic Myeloid Leukemia (CML)\|Juvenile Myelomonocytic Leukemia (JMML)\|Myelodysplastic Syndrome (MDS)\|Non-Hodgkin Lymphoma (NHL)	July 14, 2016	Phase 2
NCT02961881	Amgen	Non-Hodgkin´s Lymphoma	September 18, 2017	Phase 1
NCT04524455	Amgen	Acute Lymphoblastic Leukemia	October 2, 2020	Phase 1
NCT04554485	Institute of Hematology and Blood Transfusion, Czech Republic\|CZECRIN - Czech Clinical Research Infrastructure Network	Lymphoblastic Leukemia, Acute, Adult\|Ph Negative ALL\|Newly Diagnosed	May 9, 2019	Phase 2
NCT04827745	University of Maryland, Baltimore	Mixed Phenotype Acute Leukemia (MPAL)\|Measurable Residual Disease (MRD)	June 11, 2021	Phase 2
NCT04506086	Amgen	B-precursor Acute Lymphoblastic Leukemia	August 26, 2021	Phase 4
NCT03849651	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)\|NK-Cell Leukemia\|Hodgkin Lymphoma\|Non Hodgkin Lymphoma (NHL)\|Juvenile Myelomonocytic Leukemia (JMML)\|Chronic Myeloid Leukemia (CML)	January 31, 2019	Phase 2
NCT03121534	M.D. Anderson Cancer Center\|Amgen	Hematopoietic+Lymphoid Cancer\|Richter´s Transformation	June 22, 2017	Phase 2
NCT01741792	Amgen Research (Munich) GmbH	Diffuse Large B-cell Lymphoma	July 2012	Phase 2
NCT03023878	Amgen	High-risk Diffuse Large B-Cell Lymphoma	March 13, 2017	Phase 2
NCT04530565	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	October 14, 2020	Phase 3
NCT03518112	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Philadelphia Chromosome Negative\|Recurrent B Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia	April 18, 2018	Phase 2
NCT01371630	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative\|Burkitt-Like Lymphoma With 11q Aberration\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Burkitt Lymphoma\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Burkitt Lymphoma	August 26, 2011	Phase 1\|Phase 2
NCT04307576	Mats Heyman\|The Swedish Research Council\|The Swedish Childhood Cancer Foundation\|Pfizer\|Servier\|NordForsk\|Aamu Pediatric Cancer Foundation\|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany\|Clinical Trial Center North (CTC North GmbH & Co. KG)\|Belgium Health Care Knowledge Centre\|Karolinska Institutet\|Cancer Research UK\|Fundação Rui Osório de Castro\|Acreditar - Associação de Pais e Amigos das Crianças com Cancro\|Grupo Português De Leucemias Pediátricas\|Amgen\|Nova Laboratories Limited\|Danish Child Cancer Foundation\|Danish Cancer Society\|The Novo Nordic Foundation\|Karolinska University Hospital	Leukemia, Acute Lymphoblastic	July 13, 2020	Phase 3
NCT02879695	National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Mixed Phenotype Acute Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Mixed Phenotype Acute Leukemia	May 5, 2017	Phase 1
NCT03072771	Washington University School of Medicine\|Amgen	Diffuse Large B Cell Lymphoma	August 1, 2017	Phase 1
NCT04994717	Amgen	Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)	November 2, 2021	Phase 3
NCT02412306	Amgen\|Amgen Astellas Biopharma K.K.	Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia	June 4, 2015	Phase 1\|Phase 2
NCT04556084	Michael Burke\|Amgen\|Medical College of Wisconsin	B-cell Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Relapsed B-cell Acute Lymphoblastic Leukemia	January 1, 2021	Phase 2
NCT03147612	M.D. Anderson Cancer Center	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia With BCR-ABL1\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	February 8, 2018	Phase 2
NCT05192889	St. Jude Children´s Research Hospital\|AbbVie	Refractory Acute Lymphoblastic Leukemia\|Relapsed Acute Lymphoblastic Leukemia	August 25, 2022	Phase 1\|Phase 2
NCT04448834	Dorothy Sipkins, MD, PhD\|Amgen\|Acrotech Biopharma Inc.\|Duke University	B-cell Acute Lymphoblastic Leukemia	January 2022	Phase 2
NCT03117751	St. Jude Children´s Research Hospital\|Incyte Corporation\|Amgen\|Servier	Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Lymphoma	March 29, 2017	Phase 2\|Phase 3
NCT03709719	Assistance Publique - Hôpitaux de Paris	Acute Lymphoblastic Leukemia, Adult B-Cell	October 20, 2018	Phase 2
NCT03914625	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma\|Down Syndrome	June 28, 2019	Phase 3
NCT03523429	PETHEMA Foundation	Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL	June 30, 2018	Phase 2
NCT02744768	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia	May 31, 2017	Phase 2
NCT05182385	Goethe University\|University Hospital Schleswig-Holstein	ALL, Recurrent, Adult	December 15, 2021	Phase 1\|Phase 2
NCT02101853	National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia	December 8, 2014	Phase 3
NCT03739814	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative\|Recurrent B Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia	November 16, 2018	Phase 2
NCT02000427	Amgen	Relapsed+Refractory Philadelphia Positive B-precursor ALL	January 3, 2014	Phase 2
NCT02003222	National Cancer Institute (NCI)\|Canadian Cancer Trials Group	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	December 23, 2013	Phase 3
NCT02393859	Amgen	Leukemia, Acute Lymphoblastic	November 10, 2015	Phase 3
NCT04044560	University of British Columbia\|Amgen	B-cell Adult Acute Lymphoblastic Leukemia\|Stem Cell Leukemia\|Minimal Residual Disease	September 8, 2020	Phase 2
NCT02568553	National Cancer Institute (NCI)	Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Grade 3a Follicular Lymphoma\|Recurrent Grade 3b Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mediastinal Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Refractory Burkitt Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma\|Refractory Grade 1 Follicular Lymphoma\|Refractory Grade 2 Follicular Lymphoma\|Refractory Grade 3 Follicular Lymphoma\|Refractory Grade 3a Follicular Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Mediastinal Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Small Lymphocytic Lymphoma	June 14, 2016	Phase 1
NCT04722848	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)\|ALL, Adult\|Philadelphia-Positive ALL	September 8, 2021	Phase 3
NCT03751709	Cedars-Sinai Medical Center\|Amgen	B-Cell Acute Lymphoblastic Leukaemia\|ALL, Adult\|B-ALL	February 14, 2020	Phase 1
NCT01466179	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	December 2011	Phase 2
NCT03512405	City of Hope Medical Center\|National Cancer Institute (NCI)	CD19 Positive\|Philadelphia Chromosome Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	August 2, 2019	Phase 1\|Phase 2
NCT04521231	Amgen	B Cell Precursor Acute Lymphoblastic Leukemia	January 4, 2021	Phase 1
NCT03173430	Abramson Cancer Center of the University of Pennsylvania	Multiple Myeloma	May 27, 2017	Early Phase 1
NCT03318770	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia	May 10, 2019
NCT04688983	Cardiff University	Acute Lymphoblastic Leukemia, Adult	January 2021	Phase 2
NCT03541083	Stichting Hemato-Oncologie voor Volwassenen Nederland	ALL, Adult	June 4, 2018	Phase 2
NCT02811679	Massachusetts General Hospital\|Amgen	Non-Hodgkin Lymphoma	August 2016	Phase 2
NCT02187354	Amgen	Relapsed+Refractory B-Precursor Acute Lymphoblastic Leukemia
NCT05559450	The First Affiliated Hospital of Soochow University\|Fujian Medical University Union Hospital\|Zhongda Hospital\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|The First People´s Hospital of Changzhou\|Wuxi People´s Hospital\|First Affiliated Hospital of Wannan Medical College	B-cell Acute Lymphoblastic Leukemia	February 1, 2022	Phase 2
NCT03982992	Ludwig-Maximilians - University of Munich\|Amgen	B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation\|B-Cell Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Lymphoblastic Leukemia, Adult	June 1, 2019	Phase 2
NCT02807883	M.D. Anderson Cancer Center\|Amgen	Acute Lymphoblastic Leukemia	August 2016	Phase 2
NCT03823365	A.O. Ospedale Papa Giovanni XXIII	Indolent Non-Hodgkin Lymphomas+Chronic Lymphocytic Leukemia	December 17, 2018	Phase 1
NCT04604691	Seoul National University Hospital\|Amgen	Pediatric ALL, B Cell\|Minimal Residual Disease	February 18, 2022	Phase 1
NCT03298412	Amgen	High-risk Diffuse Large B-cell Lymphoma	May 23, 2018	Phase 2
NCT05327894	Princess Maxima Center for Pediatric Oncology\|Amgen Europe B.V\|University of Milano Bicocca	Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia	September 2022	Phase 3
NCT03643276	Martin Schrappe\|Deutsche Krebshilfe e.V., Bonn (Germany)\|University Hospital Schleswig-Holstein	Acute Lymphoblastic Leukemia, Pediatric	July 15, 2018	Phase 3
NCT04334993	Israeli Medical Association	Philadelphia-Negative ALL\|High-Risk Cancer	January 1, 2021	Phase 2
NCT01207388	Amgen Research (Munich) GmbH	B-cell Acute Lymphoblastic Leukemia	November 2010	Phase 2
NCT03114865	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Amgen	Acute Lymphoblastic Leukemia\|B-cell Non Hodgkin Lymphoma\|Pre B-Cell Acute Lymphoblastic Leukaemia	September 5, 2017	Phase 1\|Phase 2
NCT02143414	National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	January 12, 2015	Phase 2
NCT03367299	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoid Leukemia\|Philadelphia Chromosome-Negative B-Cell Precursor	June 8, 2018	Phase 2
NCT01209286	Amgen Research (Munich) GmbH	B-ALL	October 2010	Phase 2
NCT03480438	Goethe University	B-Precursor ALL	June 1, 2018	Phase 2
NCT04785547	Prof. Christina Peters\|Amgen\|St. Anna Kinderkrebsforschung	ALL, Childhood\|Minimal Residual Disease	December 17, 2020	Phase 2
NCT03931642	French Innovative Leukemia Organisation\|Amgen	Richter Syndrome	July 5, 2019	Phase 2
NCT03605589	Children´s Hospital Medical Center, Cincinnati	Leukemia, B-cell\|Lymphoma, B-Cell	September 27, 2018	Phase 1
NCT02013167	Amgen	Relapsed+Refractory B-precursor Acute Lymphoblastic Leukemia	January 3, 2014	Phase 3
NCT02877303	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma	November 1, 2016	Phase 2
NCT02997761	Brian Jonas\|National Cancer Institute (NCI)\|Pharmacyclics LLC.\|University of California, Davis	Adult B Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive	June 27, 2017	Phase 2
NCT02910063	Amgen	B-Cell Non Hodgkin Lymphoma	January 23, 2017	Phase 2\|Phase 3
NCT00274742	Amgen Research (Munich) GmbH	Non-Hodgkin´s Lymphoma, Relapsed	June 2004	Phase 1
NCT05519579	Northside Hospital, Inc.	Acute Lymphoblastic Leukemia	November 1, 2022	Phase 2
NCT04260022	Ascentage Pharma Group Inc.	Leukemia, Myeloid, Chronic\|Myeloid Leukemia\|Chronic Myeloid Leukemia\|Philadelphia Positive Acute Lymphoblastic Leukemia\|B Cell Precursor Type Acute Leukemia	January 9, 2020	Phase 1
NCT04546399	National Cancer Institute (NCI)	Down Syndrome\|Recurrent B Acute Lymphoblastic Leukemia	December 4, 2020	Phase 2
NCT04746209	Medical College of Wisconsin\|Amgen\|University of Wisconsin, Madison	B-cell Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|B-Cell ALL, Childhood	February 1, 2021	Phase 2
NCT03263572	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Amgen\|Takeda	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|BCR-ABL1 Fusion Protein Expression\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Philadelphia Chromosome Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|t(9;22)	November 29, 2017	Phase 2
NCT03340766	Amgen\|Merck Sharp & Dohme LLC	Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)	March 16, 2018	Phase 1
NCT03160079	University of California, San Diego\|Merck Sharp & Dohme LLC\|Amgen	B-Cell Acute Lymphoblastic Leukemia, Adult	August 4, 2017	Phase 1\|Phase 2
NCT01471782	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	January 2012	Phase 1\|Phase 2
NCT03109093	Goethe University	ALL, Recurrent, Adult	March 15, 2017	Phase 2
NCT02458014	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Lymphoblastic Leukemia in Complete Remission\|B Acute Lymphoblastic Leukemia\|Minimal Residual Disease\|Philadelphia Chromosome Positive	September 14, 2015	Phase 2
NCT03628053	Novartis Pharmaceuticals\|Novartis	Acute Lymphoblastic Leukemia	June 5, 2020	Phase 3
NCT03476239	Amgen	Acute Lymphoblastic Leukemia	October 18, 2017	Phase 3
NCT04329325	Memorial Sloan Kettering Cancer Center\|Amgen	Acute Lymphoblastic Leukemia\|Philadelphia Chromosome-Positive	March 30, 2020	Phase 2
NCT05557110	Chen Suning\|The First Affiliated Hospital of Soochow University	B Acute Lymphoblastic Leukemia	September 8, 2022	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847.